Coldstream Capital Management Inc. Reduces Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Coldstream Capital Management Inc. cut its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 42.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 16,472 shares of the medical research company's stock after selling 12,174 shares during the quarter. Coldstream Capital Management Inc.'s holdings in Amgen were worth $4,293,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of AMGN. Centricity Wealth Management LLC purchased a new stake in Amgen during the 4th quarter worth $25,000. Ritter Daniher Financial Advisory LLC DE increased its stake in shares of Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after acquiring an additional 51 shares during the period. Synergy Investment Management LLC acquired a new position in shares of Amgen in the 4th quarter worth approximately $34,000. Atala Financial Inc purchased a new stake in shares of Amgen during the fourth quarter valued at $34,000. Finally, Heck Capital Advisors LLC acquired a new stake in shares of Amgen in the fourth quarter worth $36,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares of the company's stock, valued at approximately $11,240,533.68. This trade represents a 40.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock valued at $20,644,335 over the last quarter. 0.69% of the stock is owned by corporate insiders.

Amgen Stock Performance

NASDAQ AMGN traded down $6.86 during trading on Friday, hitting $276.92. The company's stock had a trading volume of 2,257,809 shares, compared to its average volume of 2,787,808. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The firm has a market cap of $148.89 billion, a P/E ratio of 36.76, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The firm has a 50 day moving average price of $300.34 and a 200 day moving average price of $291.79.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. The business had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Amgen's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $3.96 earnings per share. Equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.44%. Amgen's payout ratio is currently 126.09%.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of research analyst reports. Citigroup reiterated a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Bank of America upped their target price on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research note on Wednesday, March 5th. Morgan Stanley reiterated an "equal weight" rating on shares of Amgen in a report on Friday. Wells Fargo & Company reissued an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Finally, UBS Group reiterated a "neutral" rating on shares of Amgen in a research note on Friday. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Amgen has a consensus rating of "Hold" and an average target price of $310.57.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.